{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:23:08Z","timestamp":1777332188130,"version":"3.51.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zengcheng Technology Innovation Support Fund, Guangzhou, China","award":["2024ZCKJ08"],"award-info":[{"award-number":["2024ZCKJ08"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation, China","award":["2021A1515010713"],"award-info":[{"award-number":["2021A1515010713"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-00832-7","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:38:04Z","timestamp":1747208284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dimethyl fumarate abrogates hepatocellular carcinoma growth by inhibiting Nrf2\/Bcl-xL axis and enhances sorafenib\u2019s efficacy"],"prefix":"10.1038","volume":"15","author":[{"given":"Oluwasijibomi Damola","family":"Faleti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moyed","family":"Alsaadawe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshuang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longtai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gongfa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingliang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"10127","key":"832_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391(10127), 1301\u20131314 (2018).","journal-title":"Lancet"},{"issue":"6","key":"832_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"832_CR3","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/cncr.32789","volume":"126","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990\u20132017. Cancer 126(10), 2267\u20132278 (2020).","journal-title":"Cancer"},{"issue":"2","key":"832_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.32723","volume":"147","author":"JL Petrick","year":"2020","unstructured":"Petrick, J. L. et al. International trends in hepatocellular carcinoma incidence, 1978\u20132012. Int. J. Cancer 147(2), 317\u2013330 (2020).","journal-title":"Int. J. Cancer"},{"key":"832_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctrv.2018.05.006","volume":"68","author":"JL Raoul","year":"2018","unstructured":"Raoul, J. L. et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat. Rev 68, 16\u201324 (2018).","journal-title":"Cancer Treat. Rev"},{"issue":"6","key":"832_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000499765","volume":"8","author":"L Rimassa","year":"2019","unstructured":"Rimassa, L., Pressiani, T. & Merle, P. Systemic treatment options in hepatocellular carcinoma. Liver Cancer 8(6), 427\u2013446 (2019).","journal-title":"Liver Cancer"},{"issue":"20","key":"832_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382(20), 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"832_CR8","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","volume":"27","author":"SJ Casak","year":"2021","unstructured":"Casak, S. J. et al. FDA approval summary: Atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin. Cancer Res. 27(7), 1836\u20131841 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"832_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7(1), 6 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"8","key":"832_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5306\/wjco.v11.i8.589","volume":"11","author":"AK Chow","year":"2020","unstructured":"Chow, A. K., Yau, S. W. & Ng, L. Novel molecular targets in hepatocellular carcinoma. World J. Clin. Oncol. 11(8), 589\u2013605 (2020).","journal-title":"World J. Clin. Oncol."},{"issue":"12","key":"832_CR11","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","volume":"27","author":"S Ma","year":"2008","unstructured":"Ma, S. et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway. Oncogene 27(12), 1749\u20131758 (2008).","journal-title":"Oncogene"},{"issue":"9","key":"832_CR12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.freeradbiomed.2009.07.035","volume":"47","author":"JW Kaspar","year":"2009","unstructured":"Kaspar, J. W., Niture, S. K. & Jaiswal, A. K. Nrf 2:INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med. 47(9), 1304\u20131309 (2009).","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"832_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.molmed.2016.05.002","volume":"22","author":"S Menegon","year":"2016","unstructured":"Menegon, S., Columbano, A. & Giordano, S. The dual roles of NRF2 in cancer. Trends Mol. Med. 22(7), 578\u2013593 (2016).","journal-title":"Trends Mol. Med."},{"issue":"5","key":"832_CR14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/cam4.2101","volume":"8","author":"S Wu","year":"2019","unstructured":"Wu, S., Lu, H. & Bai, Y. Nrf2 in cancers: A double-edged sword. Cancer Med. 8(5), 2252\u20132267 (2019).","journal-title":"Cancer Med."},{"issue":"6","key":"832_CR15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/ng.2256","volume":"44","author":"C Guichard","year":"2012","unstructured":"Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44(6), 694\u2013698 (2012).","journal-title":"Nat. Genet."},{"issue":"5","key":"832_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/hep.26540","volume":"58","author":"SP Cleary","year":"2013","unstructured":"Cleary, S. P. et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58(5), 1693\u20131702 (2013).","journal-title":"Hepatology"},{"issue":"4","key":"832_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cell.2019.07.031","volume":"178","author":"VR Sanghvi","year":"2019","unstructured":"Sanghvi, V. R. et al. The oncogenic action of NRF2 depends on De-glycation by fructosamine-3-kinase. Cell 178(4), 807\u2013819 (2019).","journal-title":"Cell"},{"issue":"3","key":"832_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/hep.27790","volume":"62","author":"P Zavattari","year":"2015","unstructured":"Zavattari, P. et al. Nrf2, but not beta-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology 62(3), 851\u2013862 (2015).","journal-title":"Hepatology"},{"issue":"3","key":"832_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jhep.2018.05.010","volume":"69","author":"C Orru","year":"2018","unstructured":"Orru, C. et al. Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis. J. Hepatol. 69(3), 635\u2013643 (2018).","journal-title":"J. Hepatol."},{"issue":"8","key":"832_CR20","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3390\/cancers12082305","volume":"12","author":"C Orru","year":"2020","unstructured":"Orru, C. et al. Distinct mechanisms are responsible for Nrf2-keap1 pathway activation at different stages of rat hepatocarcinogenesis. Cancers (Basel) 12(8), 2305 (2020).","journal-title":"Cancers (Basel)"},{"issue":"4","key":"832_CR21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/cas.13537","volume":"109","author":"H Kitamura","year":"2018","unstructured":"Kitamura, H. & Motohashi, H. NRF2 addiction in cancer cells. Cancer Sci. 109(4), 900\u2013911 (2018).","journal-title":"Cancer Sci."},{"key":"832_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.freeradbiomed.2012.12.014","volume":"57","author":"SK Niture","year":"2013","unstructured":"Niture, S. K. & Jaiswal, A. K. Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic. Biol. Med. 57, 119\u2013131 (2013).","journal-title":"Free Radic. Biol. Med."},{"issue":"13","key":"832_CR23","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1074\/jbc.M111.312694","volume":"287","author":"SK Niture","year":"2012","unstructured":"Niture, S. K. & Jaiswal, A. K. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J. Biol. Chem. 287(13), 9873\u20139886 (2012).","journal-title":"J. Biol. Chem."},{"issue":"9\u201310","key":"832_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0300-9084(97)82011-1","volume":"79","author":"C Cherbonnel-Lasserre","year":"1997","unstructured":"Cherbonnel-Lasserre, C. & Dosanjh, M. K. Suppression of apoptosis by overexpression of Bcl-2 or Bcl-xL promotes survival and mutagenesis after oxidative damage. Biochimie 79(9\u201310), 613\u2013617 (1997).","journal-title":"Biochimie"},{"key":"832_CR25","doi-asserted-by":"publisher","first-page":"10384","DOI":"10.1038\/ncomms10384","volume":"7","author":"S Choi","year":"2016","unstructured":"Choi, S. et al. Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nat. Commun. 7, 10384 (2016).","journal-title":"Nat. Commun."},{"issue":"8","key":"832_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1158\/1541-7786.MCR-07-0088","volume":"5","author":"S Giorgini","year":"2007","unstructured":"Giorgini, S. et al. Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol. Cancer Res. 5(8), 761\u2013771 (2007).","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"832_CR27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ijc.31075","volume":"142","author":"C Gabellini","year":"2018","unstructured":"Gabellini, C. et al. Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model. Int. J. Cancer 142(3), 584\u2013596 (2018).","journal-title":"Int. J. Cancer"},{"issue":"1","key":"832_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1053\/jhep.2001.25387","volume":"34","author":"T Takehara","year":"2001","unstructured":"Takehara, T. et al. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34(1), 55\u201361 (2001).","journal-title":"Hepatology"},{"issue":"6","key":"832_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.surg.2003.11.015","volume":"135","author":"J Watanabe","year":"2004","unstructured":"Watanabe, J. et al. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 135(6), 604\u2013612 (2004).","journal-title":"Surgery"},{"key":"832_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s12885-015-1541-1","volume":"15","author":"M Zhang","year":"2015","unstructured":"Zhang, M. et al. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer 15, 531 (2015).","journal-title":"BMC Cancer"},{"issue":"9","key":"832_CR31","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1021\/tx1001628","volume":"23","author":"N Gan","year":"2010","unstructured":"Gan, N., Sun, X. & Song, L. Activation of Nrf2 by microcystin-LR provides advantages for liver cancer cell growth. Chem. Res. Toxicol. 23(9), 1477\u20131484 (2010).","journal-title":"Chem. Res. Toxicol."},{"issue":"11","key":"832_CR32","first-page":"793","volume":"10","author":"M Meissner","year":"2012","unstructured":"Meissner, M. et al. Dimethyl fumarate-only an anti-psoriatic medication?. J. Dtsch Dermatol. Ges. 10(11), 793\u2013801 (2012).","journal-title":"J. Dtsch Dermatol. Ges."},{"issue":"7","key":"832_CR33","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1074\/jbc.M115.679704","volume":"291","author":"I Kastrati","year":"2016","unstructured":"Kastrati, I. et al. Dimethyl fumarate inhibits the nuclear factor kappaB pathway in breast cancer cells by covalent modification of p65 protein. J. Biol. Chem. 291(7), 3639\u20133647 (2016).","journal-title":"J. Biol. Chem."},{"issue":"24","key":"832_CR34","doi-asserted-by":"publisher","first-page":"11888","DOI":"10.1158\/0008-5472.CAN-06-2397","volume":"66","author":"R Loewe","year":"2006","unstructured":"Loewe, R. et al. Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res. 66(24), 11888\u201311896 (2006).","journal-title":"Cancer Res."},{"issue":"10","key":"832_CR35","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.cellbi.2009.06.027","volume":"33","author":"Y Yamazoe","year":"2009","unstructured":"Yamazoe, Y. et al. Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol. Int. 33(10), 1087\u20131094 (2009).","journal-title":"Cell Biol. Int."},{"issue":"10","key":"832_CR36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s11626-016-0069-2","volume":"52","author":"G Han","year":"2016","unstructured":"Han, G. & Zhou, Q. Dimethylfumarate induces cell cycle arrest and apoptosis via regulating intracellular redox systems in HeLa cells. In Vitro Cell Dev. Biol. Anim. 52(10), 1034\u20131041 (2016).","journal-title":"In Vitro Cell Dev. Biol. Anim."},{"key":"832_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.617714","volume":"12","author":"K Chen","year":"2021","unstructured":"Chen, K. et al. Dimethyl fumarate induces metabolic crisie to suppress pancreatic carcinoma. Front Pharmacol. 12, 617714 (2021).","journal-title":"Front Pharmacol."},{"issue":"3","key":"832_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1158\/1535-7163.MCT-16-0405","volume":"16","author":"NE Saidu","year":"2017","unstructured":"Saidu, N. E. et al. Dimethyl fumarate controls the NRF2\/DJ-1 axis in cancer cells: Therapeutic applications. Mol. Cancer Ther. 16(3), 529\u2013539 (2017).","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"832_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00972135","volume":"12","author":"S Passarella","year":"1987","unstructured":"Passarella, S. et al. Anion transport in rat brain mitochondria: Fumarate uptake via the dicarboxylate carrier. Neurochem. Res. 12(3), 255\u2013264 (1987).","journal-title":"Neurochem. Res."},{"key":"832_CR40","unstructured":"Center for Drug Evaluation and Research. Medical review: Dimethyl fumarate. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204063Orig1s000MedR.pdf"},{"issue":"Pt 3","key":"832_CR41","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"RA Linker","year":"2011","unstructured":"Linker, R. A. et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3), 678\u2013692 (2011).","journal-title":"Brain"},{"issue":"14","key":"832_CR42","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1177\/1352458517690617","volume":"23","author":"S Gopal","year":"2017","unstructured":"Gopal, S. et al. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the phase 3 DEFINE and CONFIRM studies. Mult. Scler. 23(14), 1875\u20131883 (2017).","journal-title":"Mult. Scler."},{"issue":"1","key":"832_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.molmed.2004.11.003","volume":"11","author":"U Mrowietz","year":"2005","unstructured":"Mrowietz, U. & Asadullah, K. Dimethylfumarate for psoriasis: More than a dietary curiosity. Trends Mol. Med. 11(1), 43\u201348 (2005).","journal-title":"Trends Mol. Med."},{"key":"832_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fneur.2018.00005","volume":"9","author":"EA Mills","year":"2018","unstructured":"Mills, E. A. et al. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol. 9, 5 (2018).","journal-title":"Front Neurol."},{"key":"832_CR45","first-page":"3","volume":"4","author":"Z Xu","year":"2015","unstructured":"Xu, Z. et al. Dimethyl fumarate for multiple sclerosis. Cochrane Database Systemat. Rev. 4, 3 (2015).","journal-title":"Cochrane Database Systemat. Rev."},{"issue":"2","key":"832_CR46","doi-asserted-by":"publisher","first-page":"2010000","DOI":"10.1042\/AN20100033","volume":"3","author":"SX Lin","year":"2011","unstructured":"Lin, S. X. et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 3(2), 2010000 (2011).","journal-title":"ASN Neuro"},{"issue":"2","key":"832_CR47","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4049\/jimmunol.1601649","volume":"198","author":"R Li","year":"2017","unstructured":"Li, R. et al. Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J. Immunol. 198(2), 691\u2013698 (2017).","journal-title":"J. Immunol."},{"key":"832_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1742-2094-9-163","volume":"9","author":"P Albrecht","year":"2012","unstructured":"Albrecht, P. et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J. Neuroinflamm. 9, 163 (2012).","journal-title":"J. Neuroinflamm."},{"key":"832_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.brainresbull.2020.04.005","volume":"160","author":"AL Bombeiro","year":"2020","unstructured":"Bombeiro, A. L. et al. Immunomodulation by dimethyl fumarate treatment improves mouse sciatic nerve regeneration. Brain Res. Bull. 160, 24\u201332 (2020).","journal-title":"Brain Res. Bull."},{"issue":"8","key":"832_CR50","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.biopha.2014.09.009","volume":"68","author":"M Tsubaki","year":"2014","unstructured":"Tsubaki, M. et al. Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-kappaB nuclear translocation and down-regulation of Bcl-xL and XIAP. Biomed. Pharmacother. 68(8), 999\u20131005 (2014).","journal-title":"Biomed. Pharmacother."},{"issue":"15","key":"832_CR51","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1111\/bph.13184","volume":"172","author":"X Xie","year":"2015","unstructured":"Xie, X. et al. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion\/ROS increase\/MAPKs activation pathway. Br. J. Pharmacol. 172(15), 3929\u20133943 (2015).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"832_CR52","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jdermsci.2020.07.004","volume":"99","author":"T Takeda","year":"2020","unstructured":"Takeda, T. et al. Dimethyl fumarate suppresses metastasis and growth of melanoma cells by inhibiting the nuclear translocation of NF-kappaB. J. Dermatol. Sci. 99(3), 168\u2013176 (2020).","journal-title":"J. Dermatol. Sci."},{"issue":"8","key":"832_CR53","first-page":"4713","volume":"11","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Dimethyl fumarate suppresses hepatocellular carcinoma progression via activating SOCS3\/JAK1\/STAT3 signaling pathway. Am. J. Transl. Res. 11(8), 4713\u20134725 (2019).","journal-title":"Am. J. Transl. Res."},{"issue":"6","key":"832_CR54","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1182\/blood-2016-01-694117","volume":"128","author":"JP Nicolay","year":"2016","unstructured":"Nicolay, J. P. et al. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-kappaB. Blood 128(6), 805\u2013815 (2016).","journal-title":"Blood"},{"issue":"10","key":"832_CR55","doi-asserted-by":"publisher","first-page":"13627","DOI":"10.1007\/s13277-016-5285-6","volume":"37","author":"I Kaluzki","year":"2016","unstructured":"Kaluzki, I. et al. Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation. Tumour Biol. 37(10), 13627\u201313635 (2016).","journal-title":"Tumour Biol."},{"issue":"7","key":"832_CR56","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1074\/jbc.M115.679704","volume":"291","author":"I Kastrati","year":"2016","unstructured":"Kastrati, I. et al. Dimethyl fumarate inhibits the nuclear factor B pathway in breast cancer cells by covalent modification of p65 protein. J. Biol. Chem. 291(7), 3639\u20133647 (2016).","journal-title":"J. Biol. Chem."},{"issue":"12","key":"832_CR57","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.4161\/15384047.2014.967992","volume":"15","author":"L Booth","year":"2014","unstructured":"Booth, L. et al. Regulation of dimethyl-fumarate toxicity by proteasome inhibitors. Cancer Biol. Ther. 15(12), 1646\u20131657 (2014).","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"832_CR58","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/med.21567","volume":"39","author":"NEB Saidu","year":"2019","unstructured":"Saidu, N. E. B. et al. Dimethyl fumarate, a two-edged drug: Current status and future directions. Med. Res. Rev. 39(5), 1923\u20131952 (2019).","journal-title":"Med. Res. Rev."},{"key":"832_CR59","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1158\/1538-7445.AM2016-4716","volume":"76","author":"I Kastrati","year":"2016","unstructured":"Kastrati, I. et al. Dimethyl fumarate impairs breast cancer growth and inhibits the nuclear factor kappa B pathway in breast cancer cells by covalent modification of p65. Cancer Res. 76, 4716 (2016).","journal-title":"Cancer Res."},{"issue":"4","key":"832_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","volume":"85","author":"L Baird","year":"2011","unstructured":"Baird, L. & Dinkova-Kostova, A. T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 85(4), 241\u2013272 (2011).","journal-title":"Arch. Toxicol."},{"issue":"13","key":"832_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1128\/MCB.00099-20","volume":"40","author":"L Baird","year":"2020","unstructured":"Baird, L. & Yamamoto, M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol. Cell Biol. 40(13), 93\u2013100 (2020).","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"832_CR62","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1365-2559.2012.04178.x","volume":"60","author":"NJ Yoo","year":"2012","unstructured":"Yoo, N. J. et al. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60(6), 943\u2013952 (2012).","journal-title":"Histopathology"},{"issue":"15","key":"832_CR63","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1158\/0008-5472.CAN-10-4668","volume":"71","author":"PA Konstantinopoulos","year":"2011","unstructured":"Konstantinopoulos, P. A. et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 71(15), 5081\u20135089 (2011).","journal-title":"Cancer Res."},{"issue":"4","key":"832_CR64","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1053\/j.gastro.2008.06.082","volume":"135","author":"T Shibata","year":"2008","unstructured":"Shibata, T. et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135(4), 1358\u20131368 (2008).","journal-title":"Gastroenterology"},{"issue":"5","key":"832_CR65","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2006.01.013","volume":"21","author":"B Padmanabhan","year":"2006","unstructured":"Padmanabhan, B. et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell 21(5), 689\u2013700 (2006).","journal-title":"Mol. Cell"},{"issue":"10","key":"832_CR66","doi-asserted-by":"publisher","first-page":"9088","DOI":"10.18632\/oncotarget.24144","volume":"9","author":"NE Bennett Saidu","year":"2018","unstructured":"Bennett Saidu, N. E. et al. Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. Oncotarget 9(10), 9088\u20139099 (2018).","journal-title":"Oncotarget"},{"issue":"1","key":"832_CR67","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41467-020-20171-7","volume":"12","author":"PHD Nguyen","year":"2021","unstructured":"Nguyen, P. H. D. et al. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat. Commun. 12(1), 227 (2021).","journal-title":"Nat. Commun."},{"issue":"1","key":"832_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.165","volume":"50","author":"J Liu","year":"2018","unstructured":"Liu, J., Dang, H. & Wang, X. W. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp. Mol. Med. 50(1), e416 (2018).","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"832_CR69","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00403-013-1332-y","volume":"305","author":"S Dibbert","year":"2013","unstructured":"Dibbert, S. et al. Detection of fumarate-glutathione adducts in the portal vein blood of rats: Evidence for rapid dimethylfumarate metabolism. Arch. Dermatol. Res. 305(5), 447\u2013451 (2013).","journal-title":"Arch. Dermatol. Res."},{"issue":"11","key":"832_CR70","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11910-013-0394-8","volume":"13","author":"RA Linker","year":"2013","unstructured":"Linker, R. A. & Gold, R. Dimethyl fumarate for treatment of multiple sclerosis: Mechanism of action, effectiveness, and side effects. Curr. Neurol. Neurosci. Rep. 13(11), 394 (2013).","journal-title":"Curr. Neurol. Neurosci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00832-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:04:01Z","timestamp":1747213441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00832-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00832-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were performed in compliance with the institutional guidelines and prior approval from the Animal Experimentation Ethics Committee, Southern Medical University, for the care and use of experimental animals. The study is reported in accordance with ARRIVE guidelines ().","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"16724"}}